Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183343 | 0.80 | CHRNA7 (0.40) | CHRNB4CHRNA3 | |
| SCHEMBL7512345 | 0.75 | CHRNA7 (0.52) | CHRNB4CHRNA3 | |
| SCHEMBL5345347 | 0.73 | CHRNA7 (0.36) | CHRNB4CHRNA3 | |
| SCHEMBL3195388 | 0.73 | CHRNA7 (0.40) | CHRNB4CHRNA3 | |
| SCHEMBL6979185 | 0.72 | KDM4E (0.45) | CYP1A2CHRNB4CHRNA3KMT2A | |
| SCHEMBL3243948 | 0.72 | CHRNA7 (0.39) | — | |
| SCHEMBL3242660 | 0.72 | BCAT2 (0.42) | — | |
| SCHEMBL3243643 | 0.71 | GRM5 (0.51) | — | |
| SCHEMBL5112373 | 0.71 | CHRNA7 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL5354327 | 0.71 | NPC1 (0.57) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | disclosed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | disclosed |
| EP-2172469-A1 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NeuroSearch A/S (DK) | 2010-04-07 | — | — | EP | disclosed |
| US-7674899-B2 | Dimeric azacyclic compounds and their use | NEUROSEARCH A/S (DK) | 2010-03-09 | — | — | US | disclosed |
| US-7662808-B2 | N-[4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-benzamide; disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| EP-1713487-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2009-12-02 | — | — | EP | disclosed |
| EP-1713809-B1 | DIMERIC AZACYCLIC COMPOUNDS AND THEIR USE | NEUROSEARCH AS (DK) | 2009-07-29 | — | — | EP | disclosed |
| US-20080242668-A1 | Dimeric Azacyclic Compounds and Their Use | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | US | disclosed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | disclosed |
| EP-1713809-A1 | DIMERIC AZACYCLIC COMPOUNDS AND THEIR USE | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | disclosed |
| EP-1713487-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075479-A1 | DIMERIC AZACYCLIC COMPOUNDS AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074940-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | disclosed |
| EP-1135389-B1 | 1,4-DIAZABICYCLO 3.2.2]NONANE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | SANOFI SYNTHELABO (FR) | 2003-09-10 | — | — | EP | disclosed |
| US-6407095-B1 | TREATING NICOTINIC RECEPTOR, GASTROINTESTINAL, NERVOUS SYSTEM, PSYCHOLOGICAL, AND BRAIN DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | CHRNA6, CHRNA10, CHRNA2 | CYP1A2 688/4885LMNA 2673/4885HTT 555/4885 |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | CHRNA6, CHRNA10, CHRNA2 | CYP1A2 695/4885LMNA 2706/4885HTT 556/4885 |
| US-20080242668-A1 | Dimeric Azacyclic Compounds and Their Use | CHRNA6, CHRNA5, CHRNA10 | CYP1A2 577/4885LMNA 659/4885HTT 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.